Middle East Finance

Showing 929 articles
Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

XRP's 40% Plunge: A Buying Opportunity or a Value Trap?

XRP, the cryptocurrency designed for global payments, has seen its value tumble over 40% in the past year. While its long-term promise to reshape cross-border finance remains, investors now face a critical juncture: is this a chance to buy the dip, or a sign of deeper troubles ahead?